Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Key Takeaways Eli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and ...

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill ...